ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

| More on:
A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One year ago, on 15 January 2024, you could have bought ResMed Inc (ASX: RMD) shares for $26.00 apiece.

In intraday trade today, shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company are changing hands $36.92 each. That sees the ASX 200 healthcare stock up 42% over 12 months. Or almost four times the 10.1% gains posted by the ASX 200 over this same period.

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

And that's not even including the 21.4 cents a share in unfranked dividends ResMed paid out over the year.

But with those outsized gains already come and gone, can the healthcare company keep on delivering in 2025?

According to the investing pros at Firetrail, that's very possible.

Why ResMed shares can keep charging ahead in 2025

In Firetrail's December High Conviction Fund update, the investment manager reported it had an overweight holding of ResMed shares, with the ASX 200 healthcare stock counting among the top contributors to its returns.

Firetrail noted that 2024 saw a marked turnaround for ResMed after the stock came under selling pressure in 2023 amid investor jitters over the fast rise of GLP1 drugs, which are used to help manage diabetes and obesity.

"It was back in August 2023 that concerns around the impact of GLP1 drugs drove a swift and aggressive selloff in ResMed shares," Firetrail said.

The fund manager continued:

Indeed, ResMed was among the largest detractors for the High Conviction Fund in 2023. However, throughout 2024 our bottom-up conviction and patience were rewarded as ResMed shares outperformed the ASX 200 by 35%.

In their bullish assessment for the outlook of ResMed stock in 2025, Firetrail's analysts pointed to a divergence in the company's price to earnings (P/E) ratio.

"Despite a more balanced emerging view on the impacts of GLP1s, ResMed's relative PE multiple has not recovered since the initial August 2023 selloff," Firetrail said.

Firetrail added:

ResMed's share price rise in 2024 has been entirely driven by earnings revisions. Consensus FY 2025 earnings per share (EPS) in Aussie dollars is now 26% higher than it was at the start of the year, driven by strong continued revenue growth and a recovery of gross margins.

The fund manager included the below graph to illustrate the divergence.

Summing up their optimistic outlook for ResMed shares in 2025, Firetrail said:

While the debate over the ultimate impact of GLP1s remains dynamic, we continue to see earnings upside for ResMed supported by a dominant market position and increased awareness of sleep apnoea.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Mesoblast shares dip then flip on $800,000 insider buy

The Mesoblast share price is resettling after a near-70% spike in December.

Read more »

Young investor watching share chart in anticipation
Healthcare Shares

Here's the earnings forecast out to 2029 for CSL shares

This biotech giant could see significant profit growth in the coming years.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »